Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11718408 | PMC |
| http://dx.doi.org/10.1016/j.lansea.2024.100490 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Performance and mechanisms of constructed wetland integrated microbial fuel cell for remediation and detoxification of leather tannery wastewater.
J Environ Manage
October 2024
Department of Environmental Engineering, University of Baghdad, Baghdad, Iraq. Electronic address:
Several previous studies concerned of microbial fuel cells integrated into constructed wetlands, nevertheless, their application as a convenient treatment for wastewater is still developing. In this experimental investigation, five CW-MFC systems were similarly designed, setup, and operated in a batch mode for two subsequent cycles. Each cycle lasted for 10 days to evaluate the performance of CW-MFC system for the remediation of real leather tannery wastewater (LTW).
View Article and Find Full Text PDFReal-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country.
Cancer Manag Res
January 2023
Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia.
Article Synopsis
- Anaplastic lymphoma kinase (ALK) inhibitors are effective for ALK-positive metastatic non-small cell lung cancer (NSCLC), but access is limited in developing countries like Malaysia due to financial constraints.
- A study analyzed 65 ALK-positive NSCLC patients from 18 Malaysian hospitals, finding that most received crizotinib, the most common ALK inhibitor, and showed improved overall survival (OS) compared to those on chemotherapy.
- Although ALK inhibitors led to a longer median time on treatment (TOT) and OS, the results were not statistically significant likely due to the small sample size.
Outcomes of Patients with Mutant Advanced NSCLC in a Developing Country in Southeast Asia.
Cancer Manag Res
June 2022
Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Background: Although first- and second-generation EGFR TKIs are considered first-line treatment in EGFRm+ NSCLC, most patients develop resistance and progress, commonly, EGFR mutation. The third-generation EGFR-TKI has demonstrated efficacy in patients with progressive disease harboring the mutation and in the first-line setting, bypassing this mode of resistance. The primary objectives of this study are to describe the proportion of m+ NSCLC patients treated with first-, second- and third-generation EGFR TKIs, and cytotoxic chemotherapy in the first-line setting, and the time on treatment for each category.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!